Isomorphic Labs, the AI drug discovery company spun out of DeepMind, just raised $5 billion in Series C funding. Here's what that means for the future of medicine and the European startup scene.
Isomorphic Labs, the AI-driven drug discovery company spun out of Alphabet's DeepMind, just closed a $5 billion Series C round. That's a lot of money for a company that hasn't brought a drug to market yet. But it's also a signal: investors are betting big that AI can crack the code on some of medicine's hardest problems.
The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining in. Alphabet, which spun Isomorphic out of DeepMind in 2021, also invested significantly. All existing investors—Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund—participated too. In other words, nobody wanted to sit this one out.
### Why Isomorphic Labs Matters
Isomorphic isn't your typical biotech. It's built on the idea that biology can be modeled at the molecular level and then accelerated with AI. Sir Demis Hassabis, the company's founder and CEO (and a Nobel laureate), put it this way: "Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials."
That's the pitch. And it's backed by a proprietary engine called IsoDDE, which stands for Isomorphic Drug Design Engine. IsoDDE isn't just one model—it's a suite of simulation AI models that work across multiple therapeutic areas and drug modalities. Think of it as a virtual laboratory where molecules are designed, refined, and tested before ever touching a physical lab.
Max Jaderberg, President of Isomorphic Labs, added: "Every week we are making repeatable scientific advancements enabled by our models. These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery."
### The European AI Drug Discovery Landscape
Isomorphic's raise is massive, but it's not the only game in town. Across Europe, smaller players are raising money too—though nowhere near the same league.
- **Helical** (London) raised $9.1 million for its virtual AI laboratory.
- **Ternary Therapeutics** (UK) secured $4.4 million for AI-designed molecular glues.
- **Sable Bio** (UK) attracted $3.4 million for its drug-safety platform.
- **Orakl Oncology** (France) raised $32.4 million.
- **Rivercell** (France) secured $23.8 million.
- **Adaptyv Bio** (Switzerland) announced $37.1 million for automated biological testing.
Together with other rounds, these financings represent about $160 million in 2026 funding, according to EU-Startups—excluding Isomorphic. That's a drop in the bucket compared to Isomorphic's $5 billion, but it shows a growing ecosystem.
### What's Next for Isomorphic?
The company plans to use the fresh capital to push its first therapeutic programs toward clinical trials. It's also scaling IsoDDE and its pipeline of AI-designed drug candidates. The goal? To deliver the next generation of medicines—faster and more precisely than traditional methods.
Konstantine Buhler, Partner at Sequoia Capital, said: "Isomorphic Labs is building foundational technology for the future of medicine. It's inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates. Using AI to improve human health is one of the most important challenges of our generation."
That's a sentiment many in the industry share. With this round, Isomorphic has the resources to turn that vision into reality. The question now is whether AI can truly deliver on its promise. If it does, the impact on medicine could be enormous.